Tumor microenvironmental NRG1 activation of HER3 as a driver of resistance to PI3K pathway inhibition in prostate cancer.

Xtandi (enzalutamide) - Pfizer, Astellas

sapanisertib (CB-228) - Calithera

seribantumab (MM-121) - Concentra Biosciences

pictilisib (GDC-0941) - Roche

Truqap (capivasertib) - AstraZeneca

lapatinib - Generic mfg.

https://www.asco.org/abstracts-presentations/256618

Kevin Shee; Lingru Xue; Vishvak Subramanyam; Todd Golub; Todd W. Miller; Peter Carroll; Ravid Straussman; Hao G. Nguyen

Jan 20, 2026